View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Theme
  2. Macro
  3. Covid-19
October 22, 2020

Coronavirus company news summary – Ecuador signs Covid-19 supply deals – AstraZeneca vaccine trial to continue despite death of Brazilian participant in placebo group

By Allie Nawrat

22 October 2020 

Anvisa, the Brazilian healthcare regulator, has reported the death of a volunteer involved in AstraZeneca and University of Oxford Covid-19 vaccine trial being carried out in Brazil. Anvisa has confirmed that trial will continue as the volunteer was part of the placebo group. This was later confirmed by the University of Oxford, according to Reuters.

Poseida Therapeutics and TScan Therapeutics are collaborating to explore the efficacy of TCR-T cell therapies to treat Covid-19. The partnership will leverage TScan’s TCR sequences and immunodominant epitopes and Poseida’s allogeneic T cell approach to advance TCR-T cell therapies against Covid-19.

Dr Juan Carlos Zevallos, the health minister of Ecuador, announced that the country has entered into Covid-19 vaccine supply agreements with pharmaceutical companies, such as Pfizer and BioNTech, for Covid-19 vaccines. The country is also collaborating with Chinese laboratories for supplies and is funded by the Inter-American Development Bank to gain access to the COVAX vaccine, he added.

Researchers from the University of Tennessee Health Science Center and the University of New Mexico have identified zuclopenthixol, nebivolol, and amodiaquine drugs as efficacious therapeutics to fight the SARS-CoV-2 virus. The drugs are already approved for human use and have been found to be effective in  the earlier stages of Covid-19.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology